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Antimicrobial peptides are generated during activation of the complement system [Nordahl et al. Proc. Natl. Acad. Sci. U. S. A. 2004,
101:16879-16884]. Here we show that the anaphylatoxin C3a exerts antimicrobial effects against the yeast Candida. Fluorescence microscopy
and electron microscopy analysis demonstrated that C3a-derived peptides bound to the cell surface of Candida, and induced membrane
perturbations and release of extracellular material. Various Candida isolates were found to induce complement degradation, leading to generation
of C3a. Arginine residues were found to be critical for the antifungal and membrane breaking activity of a C3a-derived antimicrobial peptide,
CNY21 (C3a; Cys57–Arg77). A CNY21 variant with increased positive net charge displayed enhanced antifungal activity. Thus, C3a-derived
peptides can be utilized as templates in the development of peptide-based antifungal therapies.
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The innate immune system, based on antimicrobial
peptides (AMP), provides a rapid and non-specific response
against potentially invasive pathogenic microorganisms. At
present, over 880 different AMPs have been identified in
eukaryotes (www.bbcm.univ.trieste.it/~tossi/pag5.htm). The
endogeneous AMPs cathelicidin LL-37/hCAP18, β-defensins,
RNase 7, various dermcidins as well as psoriasin are found in
skin [1–5]. The significance of cathelicidins for bacterialAbbreviations: AMP, antimicrobial peptides; CF, carboxyfluorescein; cfu,
colony-forming units; DOPA, 1,2-Dioleoyl-sn-Glycero-3-Phosphate, monoso-
dium salt; DOPC, 1,2-dioleoyl-sn-Glycero-3-phosphocholine; Low-EEO, low-
electroendosmotisistype agarose gel; MALDI-TOF, matrix-assisted laser
desorption/ionization time-of-flight; MEC, minimal effective concentration;
RDA, radial diffusion assay; TAMRA, Tetramethylrhodamine; YPD, yeast
extract-peptone-dextrose
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doi:10.1016/j.bbamem.2006.10.017clearance is exemplified by findings indicating that the mouse
antibacterial cathelicidin peptide CRAMP protects the skin
from invasive bacterial infection [6]. Furthermore, molecules
previously not considered as AMPs, including proinflamma-
tory and chemotactic chemokines exert antibacterial and
antifungal activities [7]. The proinflammatory, chemotactic,
and anaphylatoxic peptide C3a, generated during activation of
the complement system [8,9] displays potent antibacterial
effects [10]. In general, AMPs interact with microbial
membranes and subsequent events involve membrane desta-
bilization and permeabilization and/or interaction with
intracellular targets, ultimately leading to microbial killing
[11–16]. Structural prerequisites for peptide action have been
studied in great detail in several structure–activity relationship
studies, and multiple parameters including conformation, net
charge, size, degree of amphipathicity and hydrophobicity
govern the antimicrobial activity of AMPs [11,17–19].
Structural differences between bacterial, fungal, and mamma-
lian cell surfaces underlie a certain degree of selectivity for
AMP action and many peptides may preferentially target
Fig. 1. Sequence and molecular model of C3a and peptides used in the study.
The peptides LTE21, LRK26, LGE27 and CNY21 are indicated in the sequence.
The peptides corresponding to regions CNY21 (violet) and LRK26 (blue)
exerted anticandidial activity. Lysine and arginine residues of these regions are
visualized.
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[16,20]. Thus, bacterial surfaces contain many anionic
components, including LPS and anionic lipids of Gram-
negative bacteria, as well as teichoic and teichuronic acids of
Gram-positive bacteria. Similarly, β-glucan, chitin, manno-
protein and a blend of other cell wall proteins and
polysaccharides contribute to a negative surface potential of
fungal surfaces [21–23]. Beyond the outer cell surface, AMPs
interact with the plasma membrane. Contrasting to eukaryotic
membranes, including fungal membranes, which contain
mostly zwitterionic lipids (such as phosphatidylcholine),
bacterial membranes comprise various acidic phospholipids
(phosphatidylglycerol, phosphatidylserine and cardiolipin),
which confer a negative charge facilitating AMP binding
and sometimes also defect formation [5,12,16]. The plasma
membrane of eukaryotic cells contains sphingolipids andTable 1
Complement factor C3-derived peptides analysed in the study
Peptide Sequence Mw (Da)
CNY21 CNYITELRRQHARASHLGLAR 2465.83
CNY21H-K CNYITELRRQKARASKLGLAR 2447.89
CNY21H-L CNYITELRRQLARASLLGLAR 2417.87
CNY21H-P CNYITELRRQPARASPLGLAR 2385.78
CNY21R-S CNYITELSSQHASASHLGLAR 2258.5
Mw, molecular weight. Da, Dalton. The parameters are set at pH 7.40, temperature 27
indicate amino acid substitutions.
a pI, the theoretical isoelectric point calculated by using the Protparam tool avail
b Agadir is a prediction algorithm based on the helix/coil transition theory that
embl-heidelberg.de/Services/serrano/agadir/agadir-start.html.
c Relative hydrophobic moment (μHrel) was calculated by using HydroMCalc (Ky
HydroMCalc.html.sterols, which are missing in prokaryotes [24], and which are
frequently found to provide some resistance to AMP
membrane rupture [5,25,26]. Ergosterol is the major sterol
in yeasts, whereas the sterol in plasma membranes of
mammalian cells is represented by cholesterol [24]. All
these factors contribute to AMPs exhibiting different activity
spectra on bacterial and fungal membranes, as well as toxicity
on eukaryotic cells. It has, however, become increasingly
clear that AMP selectivity may also depend on factors such as
AMP oligomerisation and preassembly (in solution and
membrane) [27].
Candida is a dimorphous fungus colonizing the mucous
membranes of the mouth and vagina in a saprophytic
manner. However, Candida is also known to be involved in
several diseases such as cutaneous infections, atopic eczema,
oroesophageal candidiasis, candida vaginosis and septicaemia
[21,28]. In animal models of cutaneous candidiasis it has
been shown that Candida activates the complement system
and C3 fragments are deposited at the cell surface of
Candida [29–31]. In humans, generation of C3a has been
implicated in the pathogenesis of skin diseases, such as
atopic dermatitis [32,33]. Conversely, C. albicans may also
inhibit the alternative and classical pathways of complement
activation by binding factor H, FHL-1, and C4b-binding
protein [34,35].
In the present study we investigated whether C3a-like
peptides, generated in response to Candida infection, exert
antifungal effects. Our data disclose a novel antifungal activity
of C3a and functional epitopes of C3a. Amino acid alterations in
a C3a-derived peptide were performed to elucidate structural
requirements for peptide action as well as enhance peptide
activity. The findings can be utilized in the further development
of C3a-derived peptides for therapeutic use.
2. Materials and methods
2.1. C3-derived peptides and LL-37
C3a was obtained from Calbiochem. The peptides LTE21, LRK26,
LGE27, CNY21, CNY21H-K, CNY21H-L, CNY21H-P, CNY21R-S, LL37,
(Fig. 1 and Table 1), Tetramethylrhodamine (TAMRA)-conjugated CNY21
and LRK26 were all synthesized by Innovagen AB (Lund, Sweden). The
purity (>95%) and molecular weight of these peptides was confirmed by masspI a Net charge AGADIRb μHrel c
10.7 +3 4.8 0.28
10.9 +5 9.7 0.27
10.7 +3 17.9 0.34
10.7 +3 1.9 0.28
6.9 0 0.6 0.24
8 K (5 °C), ionic strength 0.150 M, N-terminal and C-terminal free. Bold letters
able at http://us.expasy.org/tools/protparam.html.
predicts the helical behavior of monomeric peptides available at http://www.
te and Doolittle) available at http://www.bbcm.univ.trieste.it/~tossi/HydroCalc/
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CA, USA).
2.2. Assays for candidacidal activities
C. albicans ATCC 90028 was obtained from the Department of
Bacteriology at Lund University Hospital. Clinical Candida albicans and
parapsilosis isolates were obtained from patients with atopic dermatitis.
Cells were precultured over night on Sabouraud–dextrose–agar (Difco,
Detroit, MI) at 28 °C, inoculated in 10 ml yeast extract–peptone–dextrose
(YPD) broth (Sigma-Aldrich, St. Louis, USA) at 28 °C and grown to mid-
logarithmic phase. The cells were washed three times and diluted in 10 mM
Tris, pH 7.4. Fifty μl of a suspension containing 1×106 fungal cfu/ml wasFig. 2. Antimicrobial activity of C3a and C3a-derived peptides againstC. albicansAT
with 50 μMof the peptides. Standard error of themean (SEM) are indicated. C3awas s
significant difference (P<0.001; n = 9). (B) The indicated peptides (6 μl each at 100 μ
usingC. albicans, LRK26 and CNY21 showed anticandidial activity. For comparison
Candida albicansATCC 90028 and inhibition of binding by heparin. Panels 2 and 6 sh
(10 μg ml−1) and panels 4 and 8 show yeast cells incubated with heparin and the co
recorded using identical instrument settings. The corresponding Nomarski images a
peptides and LL-37. Candida cell suspensions (1×106) were incubated with the peptid
LL37 andCNY21R-S served as positive and negative controls, respectively. Panel 1 sh
CNY21 and LL-37, respectively and panels 3, 5, and 7 show the corresponding peptincubated at 28 °C for 2 h with C3a, LL37, or the peptides CNY21,
CNY21H-K, CNY21H-L at concentrations ranging from 0 to 6 μM (for C3a)
and 0 to 30 μM (for the other peptides). To quantify the fungicidal activity,
serial dilutions of the incubation mixture were plated onto Sabouraud-
dextrose-agar (Difco, Detroit, MI) plates and incubated 48 h at 28 °C, the
number of colony-forming units (cfu) were thereafter determined by counting
visible colonies.
Radial diffusion assay (RDA) was performed as described by Lehrer et al.
[36] with some minor modifications. Candida was grown for 16 h at 28 °C in
10 ml YPD to obtain yeast form organisms. The culture was then centrifuged
at 2000×g for 10 min, washed three times with 10 mM Tris, pH 7.4. A
volume containing 1×105 cfu was added to 5 ml of previously autoclaved,
warm 42 °C, underlay agarose gel that contained 1.5 mg of TSB, 50 mg ofCC 90028. (A) C3a and LL37 were tested in RDA, each well was loaded with 6 μl
ignificantlymore potent than the control peptide LL37; ***indicates a statistically
M), spanning different helical regions of the C3a molecule, were tested in RDA
LL37 was used (n=8). (C) Binding of TAMRA-CNY21 and TAMRA-LRK26 to
ows red fluorescence ofCandida cells stained with TAMRA-conjugated peptides
rresponding TAMRA-conjugated peptides. Images in panels 2, 4, 6, and 8 were
re shown in panels 1, 3, 5 and 7. (D) Treatment of Candida with C3a-derived
es, absorbed to glass coverslips and visualized by scanning electron microscopy.
owsCandida cells alone, Panels 2, 4, and 6 show effects of 50 μMof CNY21R-S,
ides at 100 μM. Scale bar represents 10 μm.
Fig. 3. Generation of C3a-derived peptides in human serum. Human serum was
incubated with Candida ATCC90028, and C3a-peptides were detected by
immunoblotting using polyclonal antibodies against the C3a-derived peptide
LGE27. (A) Serum was incubated for the indicated time periods (bottom) in
absence (−) or presence (+) of Candida albicans ATCC 90028. (B) Serum was
incubated for 4 h alone (Ctr) or with various clinical isolates of Candida
albicans (CA1–3) and Candida parapsilosis (CP 1 and 2) derived from the skin
of patients with atopic dermatitis. In both panels, molecular mass markers are
indicated on the left. The arrow indicates the position of intact C3a.
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Louis, MO USA, A-6013-25G) and 1 μl of Tween 20 (0.02%w/v) (Sigma
Chemical Co.) dissolved in 10 mM Tris, pH 7.4. The fungi were directly
dispensed into the agar and mixed with a vortex mixer for 10 s and then
quickly poured out into a Petri dish, 85 mm in diameter. Wells, 4 mm in
diameter, were punched and each well was then filled up with 6 μl of test
sample. After incubation in 35–37 °C for 3 h, 5 ml of overlay agarose gel,
consisting of 300 mg TSB, 50 mg Low-EEO dissolved in distilled sterilized
water, was poured out on top of the underlay agarose gel. A clear zone
surrounding the wells indicated antibacterial activity and was measured after
18–24 h of incubation at 28 °C. The minimal effective concentration (MEC)
was obtained by plotting the zone diameter and logarithmic concentration of
the peptides, then using the x intercept value calculated from a linear
regression analysis in SigmaStat (Systat Software Inc., Point Richmond, CA,
USA).
2.3. Fluorescence microscopy
C. albicans ATCC 90028 was incubated for 17 h in 10 ml YPD-broth at
28 °C to obtain mid-logarithmic phase organisms and washed three times,
then diluted in 10 mM Tris, pH 7.4 to a concentration of 1×107 cfu/ml. Two
hundred μl samples of the C. albicans suspension was incubated for 5 min on
ice together with 1 μl TAMRA-CNY21 or TAMRA-LRK26 (2 mg/ml). For
blocking of binding of CNY21 and LRK26 to the fungal membrane, 2 μl
heparin (50 mg/ml) was added to the samples prior to incubation with
TAMRA-CNY21 and TAMRA-LRK26. The pellets were washed three times
in 10 mM Tris, pH 7.4. Cell FIX (Becton Dickinson Catalogue No. 340181)
was added (to a final concentration of 4% formaldehyde) and the yeast cell
pellets were incubated 15 min on ice and then 45 min in room temperature.
Ethanol washed glass cover slips were coated with 0.25 ml of poly-lysine
(0.2 mg/ml dissolved in water), dried and then washed with distilled water.
The samples were adhered to the poly-lysine glasses for 30 min and mounted
on microscope slides for visual inspection. A Nikon Eclipse TE300 inverted
fluorescence microscope was used.
2.4. Electron microscopy
C. albicans ATCC 90028 cells (1×106 cells per sample) were incubated
for 2 h with 50 μM and 100 μM of CNY21R-S, CNY21 or LL-37.
C. albicans cells incubated in 10 mM Tris buffer, pH 7.4 only, were included
for control. The samples were fixed in 2.5% (v/v) glutaraldehyde in 0.15 M
sodium cacodylate, pH 7.2, incubated at room temperature over night and
washed 4×10 min in 0.15 M sodium cacodylate, pH 7.2. Samples were
washed with cacodylate buffer, and dehydrated with an ascending ethanol
series from 50% (v/v) to absolute ethanol (10 min per step). The material was
then critical point dried in carbon dioxide, with absolute ethanol as
intermediate solvent, mounted on aluminium holders and sputtered with
50 nm palladium/gold. They were examined in a JEOL JSM-350 scanning
electron microscope operated at 5 kV.
2.5. Liposome preparation and leakage assay
Dry lipid films were prepared by dissolving either dioleoylphosphatidylcho-
line (Avanti Polar Lipids, Alabaster, AL) (60 mol%) and cholesterol (Sigma, St.
Louis, MO) (40 mol%; added for reducing spontaneous liposome leakage to less
than a couple of % over the time-scale of the experiment), or dioleoylpho-
sphatidic acid (Avanti Polar Lipids, Alabaster, AL) (30 mol%), dioleoylpho-
sphatidylcholine (30 mol%), and cholesterol (40 mol%) in chloroform, and then
removing the solvent by evaporation under vacuum overnight. Subsequently,
buffer (10 mM Tris, pH 7.4) was added together with 0.1 M carboxyfluorescein
(CF) (Sigma, St. Louis, MO). After hydration, the lipid mixture was subjected to
eight freeze–thaw cycles consisting of freezing in liquid nitrogen and heating to
60 °C. Unilamellar liposomes, of about ∅140 nm were generated by multiple
extrusions through polycarbonate filters (pore size 100 nm) mounted in a
LipoFast miniextruder (Avestin, Ottawa, Canada) at 22 °C. Untrapped
carboxyfluorescein was then removed by two gel filtrations (Sephadex G-50)
at 22 °C, with Tris buffer as eluent.In the liposome leakage assay, self-quenching of CF was used. Thus, at
100 mM CF is self-quenched, and the recorded fluorescence intensity from
liposomes with entrapped CF is low. On leakage from the liposomes, released CF
is dequenched, and hence fluoresces. The CF release was determined by
monitoring the emitted fluorescence at 520 nm from a liposome dispersion
(10 mM lipid in 10 mM Tris pH 7.4). An absolute leakage scale is obtained by
disrupting the liposomes at the end of the experiment through addition of 0.8 mM
Triton X100 (Sigma, St. Louis, MO), thereby causing 100% release and
dequenching of CF. A SPEX-fluorolog 1650 0.22-m double spectrometer (SPEX
Industries, Edison, NJ) was used for the liposome leakage assay. Measurements
were performed at 37 °C. The liposomes investigated were either zwitterionic
(DOPC/cholesterol 60/40 mol/mol) or anionic (DOPC/DOPA/cholesterol 30/30/
40 mol/mol). DOPA (1,2-Dioleoyl-sn-Glycero-3-Phosphate, monosodium salt)
and DOPC (1,2-dioleoyl-sn-Glycero-3-phoshocholine) were both from Avanti
Polar Lipids (Alabaster, USA) and of >99% purity, while cholesterol (>99%
purity), was from Sigma-Aldrich (St. Louis, USA).
2.6. Generation of C3a-derived peptides in human serum
Human serum was incubated with C. albicans strain ATCC 90028
(1×108 cells) or clinical Candida isolates for up to 4 h at 28 °C in
polypropylene tubes (total volume of 1 ml). For kinetic study of the effects of
C. albicans strain ATCC 90028, 150 μl was drawn from the mixture at 0, 1.5,
and 4 h and then centrifuged at 14,000 rpm. The pellet, containing Candida
cells was washed three times in 10 mM Tris, pH 7.4 and stored in −20 °C.
The supernatants were analysed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) on a 16.5% Tris–Tricine gel (Bio-Rad
Laboratories, Hercules, CA) under reducing conditions, and then transferred
onto nitrocellulose membranes (Hybond-C, Amersham Life Sciences).
Membranes were blocked using 3% (w/v) skimmed milk (ICN Biomedicals
Inc., Ohio, USA) in blocking buffer (50 ml 1 M Tris, pH 7.4, 10 ml Tween
20, 43.8 g NaCl in 500 ml water) and then washed in the buffer three times.
The membranes were then incubated with rabbit polyclonal antibodies
(Innovagen) against the peptide LGE27 (at 1:1000). After three washes the
membranes were incubated with horseradish peroxidase-conjugated swine
anti-rabbit secondary antibodies (DAKO A/S, Glostrup, Denmark) (1:1000).
The proteins reacting with the antibodies were detected by using enhanced
chemiluminescence ECLWestern Blotting Detection Reagents Kit (Amersham
Biosciences, Buckinghamshire, UK).
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Statistical analysis of the difference between zone diameters of C3a and LL-
37 in RDA (Fig. 1A) was performed using the Mann–Whitney Rank Sum Test.
Comparison of antifungal activity between CNY21 and the various synthesized
CNY21 variants (Fig. 4B) was performed using Kruskal–Wallis One Way
Analysis of Variance on Ranks and pair ways multiple comparison procedures
(Tukey Test). P<0.05 was considered as a significant difference. The statistical
software used was SigmaStat (Systat Software Inc., Point Richmond, CA,
USA).3. Results and discussion
To investigate whether the anaphylatoxin peptide C3a
possessed antifungal activity, we investigated the effects of
purified C3a on a Candida albicans isolate. The results showed
that C3a (for sequence see Fig. 1) was indeed active against
Candida and notably, the peptide exerted a stronger inhibitory
effect in the RDA assay when compared with the classical AMP
LL-37 (both at 50 μM) under the low-salt conditions used (Fig.
2A). In viable count assays, the concentrations of C3a and LL37
required to kill 50% of the microorganisms were calculated toFig. 4. Antifungal activities of CNY21 and variants thereof. (A) The helical wheel
amino acids in the modified variants 1CNY21H-K, 2CNY21H-L, 3CNY21H-P and 4
charged amino acids by blue circles. The uncharged Y, G, S, C, and T and the polar am
Table 1 for sequences. (B) RDA analysis of antifungal effects of the CNY21 varian
inhibition zones than native CNY21, whereas CNY21R-S was inactive, * indicates
concentrations (MEC) of CNY21 and CNY21H-K were investigated by RDA. The M
MEC values obtained were 8.9 μM and 2.9 μM for CNY21 and CNY21H-K, res
logarithmic. (D) Antimicrobial activity of CNY21 variants (100 μM) against clinical
For all isolates, CNY21H-K yielded larger inhibition zones than CNY21 and LL-375.0 μM and 11.5 μM, respectively. In order to determine which
regions of C3a were responsible for the antifungal activity,
overlapping fragments (Fig. 1), encompassing different helical
regions of the C3a molecule were synthesized and tested for
antifungal activities. Whereas the peptides LTE21 and LGE27
displayed no antimicrobial effects, the peptides LRK26 and
CNY21 (Fig. 1) exerted potent antifungal activities in RDA
against C. albicans ATCC 90028 (Fig. 2B). To investigate
whether the peptides CNY21 and LRK26 bind to Candida, the
peptides were labelled with the fluorescent dye TAMRA and
incubated with the fungal cells. As demonstrated by fluores-
cence microscopy, both peptides bound to the surface of Can-
dida, and the binding was completely blocked by heparin (Fig.
2C). Heparin did not quench the fluorescence of the TAMRA
label (not shown). The well-defined carboxyterminal region of
C3a, comprising CNY21 may adopt a helical conformation [9],
and harbors typical features of helical AMPs [17]. Thus, in
mice, a peptide corresponding to this region was protective
against infection by the significant human pathogen Strepto-
coccus pyogenes [10]. Furthermore, human neutrophilic
enzymes release peptides exerting antimicrobial effects whichprojection shows CNY21 assuming an α-helical conformation. The substituted
CNY21R-S are indicated. Hydrophobic amino acids are represented by red and
ino acids N and Q are indicated by grey and green circles, respectively. See also
ts. All peptides were tested at 100 μM. CNY21H-K yielded significantly larger
a statistically significant difference (P<0.05; n=11). (C) The minimal effective
EC-values are defined by the intersections of the regression lines with the x axis.
pectively. Note that the scale of the x axis (concentrations of the peptides) is
isolates of Candida albicans (CA 1–3) and Candida parapsilosis (CP 1 and 2).
. Error bars indicate SEM.
Fig. 5. CF leakage of from (A) anionic (DOPC/DOPA/cholesterol) and (B)
zwitterionic (DOPC/cholesterol) liposomes induced by CNY21 (circle),
CNY21H-L (diamond), CNY21H-K (triangle down), CNYH-P (square) and
CNY21R-S (triangle up). In (B) the data sets of CNY21P and CNY21R-S
overlap each other. The concentration of peptide used is 1 μM.
351A. Sonesson et al. / Biochimica et Biophysica Acta 1768 (2007) 346–353contain the carboxyterminal region of C3a (comprising
CNY21), proving the physiological importance of this anti-
microbial region of C3a [10]. Thus, the following experiments
focused on CNY21. To further analyze the effects of this
peptide on the yeast cells, Candida cells were incubated with
the peptide CNY21, and analyzed by scanning electron
microscopy. The human cathelicidin LL-37 was included for
comparison and a CNY21-derived peptide containing the
anaphylatoxin determinant LGLAR, but totally devoid of
antibacterial activity [10], CNY21R-S (Table 1), was used as
negative control. Compared with the control cells, CNY21-
treated Candida cells displayed extracellular material and
membrane perturbations. The cells treated with LL-37 showed
significant perturbations of the cell surface, although less
extracellular material was detected (Fig. 2D).
Having shown the antifungal activities of C3a and derived
peptides, we explored whether Candida could generate similar
C3a-like peptides in human serum. Western blot analysis using
antibodies against the C3a-epitope LGE27 (containing a major
part of CNY21), demonstrated that peptides corresponding to
C3a were indeed formed in serum subjected to Candida
albicans ATCC 90028 (Fig. 3A). A similar finding was
obtained with five other clinical Candida isolates derived
from patients with atopic dermatitis (Fig. 3B), thus presenting a
proof of the concept that antimicrobial peptides may indeed be
generated in response to Candida infection. Clearly, consider-
ing the multifunctionality of C3a, as well as the high
redundancy of innate immune defences, the physiological in
vivo significance of the herein presented direct antifungal
activity of C3a needs to be determined. C3 is found in saliva as
well as in vaginal fluid [37,38]. In blood, the concentration of
C3 is 5–11 μM. Furthermore C3 is produced by endothelial
cells, keratinocytes and monocytes [39–41]. Hence, comple-
ment activation in response to Candida infection should
therefore induce generation of C3a at antifungal concentrations.
Various factors, such as net charge, hydrophobicity, and
degree of amphipathicity govern the activity of AMPs.
Concerning the group of peptides comprising α-helices, helix-
stabilizing or destabilizing amino acids affect both antimicrobial
as well as hemolytic activities [17,42]. Notably, introduction of
polar or charged amino acid residues at hydrophobic regions of
AMPs may result in improved therapeutic index, i.e. increase of
antimicrobial activity with no concomitant increase of hemolysis
[43]. In order to determine the structural requirements of CNY21
and its actions against Candida, we modified the net charge,
hydrophobicity, as well as helical propensity of the peptide
CNY21 (Table 1 and Fig. 4A). Replacement of the two histidine
residues by lysine (CNY21H-K) significantly increased the
antifungal activity, whereas the peptide CNY21H-L exerted
similar antimicrobial effects as the native peptide. The MEC
values for CNY21 and CNY21H-K, determined by RDA, were
8.9 μM and 2.9 μM, respectively (Fig. 4C). Analogous results
were obtained in viable count assays. The concentrations of
CNY21 and CNY21H-K required to kill 50% of the micro-
organisms were 9.25 μM and 5.9 μM, respectively. Introduction
of helix breaking proline residues (CNY21H-P) significantly
reduced the activity of the peptide, suggesting that a helicalconformation is a prerequisite for action on Candida mem-
branes. Replacement of the central three arginines by the polar
residue serine completely abolished the antimicrobial activity of
CNY21 (Fig. 4B). Corroborating findings were obtained using
five clinicalCandida isolates (Fig. 4D). In all cases, CNY21H-K
yielded zones significantly larger than those obtained for
CNY21, CNY21H-L, or LL-37. Notably, one Candida isolate
(CA2) was completely resistant to LL-37. For zwitterionic and
anionic liposomes, the membrane-disruptive potency for
CNY21-variants increased with increasing net positive charge
and mean hydrophobicity of the peptide, and was completely
lost on elimination of all peptide positive charges (Fig. 5).
Interestingly, the H->P substituted peptide retained some
activity on negatively charged liposomes. In this context, it
should be emphasized that the purpose of using zwitterionic and
anionic liposomes was not to mimic fungal or eukaryotic cells or
bacterial membranes, respectively, but merely to monitor the
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Cholesterol was added to reduce spontaneous leakage from the
liposomes to less than 2% during the time-scale of the
experiment, in an effort to provide the highest possible quality
of the leakage data. Nevertheless, the results are compatible with
the current view of AMP functions, and indicate that a positive
net charge, hydrophobicity, and a partial helical conformation
are required for the antifungal and membrane-breaking action of
CNY21.
Interestingly, neither CNY21 nor the CNY21 variants
exerted any hemolytic effects on human erythrocytes and they
did not permeabilize a human keratinocyte cell line [44]. The
origin of the selectivity of the peptides investigated to fungi
over other eukaryotic cells is unclear at present. Possibly,
differences between erythrocytes and fungi in terms of sterol
content could contribute to this increased peptide resistance of
the former, as cholesterol possesses strongly membrane-
stabilizing properties [45] and ergosterol has been found to
induce less membrane stability in phospholipids than choles-
terol [46]. Furthermore, although the z-potential of fungi and
platelets is quite similar [47,48], this parameter depends
sensitively on the material and charge distributions normal to
the cell interface. It is therefore possible that differences in the
latter may contribute to the observed selectivity as well, through
differences in the local electrostatic peptide accumulation.
Clearly, the exact mechanisms that determine the sensitivity of
Candida to C3a-derived AMPs need further investigation. It is
therefore interesting to note that Avrahami and Shai have
demonstrated an approach for study of AMPs with antifungal
activities using model membranes having a lipid composition
resembling the bilayer of C. albicans [49,50]. Concludingly, the
herein presented results indicate that C3a-derived peptides
could be used in further studies of AMP interactions with
Candida as well as provide interesting templates for the
development of novel antifungal AMPs.
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